Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Duloxetine hydrochloride
Drug ID BADD_D00735
Description Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686.[A178741] Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder.[L6454] It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.
Indications and Usage **Indicated** for: 1) Management of Major Depressive Disorder.[label] 2) Management of Generalized Anxiety Disorder.[label] 3) Management of diabetic peripheral neuropathy.[label] 4) Management of fibromyalgia.[label] 5) Management of chronic musculoskeletal pain.[label] 6) Management of osteoarthritis of the knee in adults.[L6364] 7) Management of chronic lower back pain in adults.[L6364] 8) Management of stress urinary incontinence in adult women.[L6367] **Off-label** uses include: 1) Management of chemotherapy-induced peripheral neuropathy.[A178603] 2) Management of stress urinary incontinence in adult men after prostatectomy until recovery is complete.[L6370]
Marketing Status approved
ATC Code N06AX21
DrugBank ID DB00476
KEGG ID D01179
MeSH ID D000068736
PubChem ID 60834
TTD Drug ID D01AXB
NDC Product Code 0110-3235; 43063-877; 43353-960; 50090-3205; 51991-746; 59651-280; 60687-745; 71335-0392; 71610-401; 0110-3270; 0110-9542; 0904-7043; 59651-282; 62128-0386; 73476-750; 51407-817; 63187-720; 82009-032; 65015-713; 25000-610; 33342-161; 43353-106; 51407-818; 57237-019; 63187-181; 63187-612; 68001-413; 57237-018; 61919-482; 63629-1990; 68788-8362; 71335-0165; 55111-859; 55745-0004; 59651-279; 68071-2711; 68788-7897; 71335-0509; 71610-402; 82009-029; 82009-030; 0110-9544; 49587-111; 73476-747; 25000-609; 60429-164; 60429-166; 60687-723; 61919-042; 68001-414; 68001-415; 82009-031; 0904-7044; 43353-025; 45865-815; 50090-2226; 55154-2341; 70518-0937; 0110-9543; 17337-0017; 51927-0059; 71554-015; 73476-746; 33342-162; 0002-3270; 51407-819; 60429-165; 63187-716; 63629-1991; 63629-2063; 68788-9301; 59286-1046; 68108-0705; 25000-608; 33342-160; 0002-3235; 43063-878; 51991-747; 51991-748; 60505-2995; 60687-734; 63187-666; 63187-702; 63187-735; 63629-1992; 63629-9187; 17337-0046; 73476-748; 0002-3240; 51991-750; 55154-2342; 57237-017; 63187-172; 68001-368; 71610-218; 0110-3240; 0110-9545; 14501-0005; 0904-7045; 51927-4999; 65862-463
UNII 9044SC542W
Synonyms Duloxetine Hydrochloride | Hydrochloride, Duloxetine | Duloxetine HCl | HCl, Duloxetine | LY 248686 | LY-248686 | LY248686 | Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987 | LY 227942 | LY-227942 | LY227942 | Duloxetine | N-methyl-3-(1-naphthalenyloxy)-3-(2-thiophene)propanamide | N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine | Duloxetine, (+)-isomer | Cymbalta
Chemical Information
Molecular Formula C18H20ClNOS
CAS Registry Number 136434-34-9
SMILES CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Weight increased13.15.01.006--
White blood cell count increased13.01.06.013--Not Available
Yawning22.12.03.037--Not Available
Seasonal allergy22.04.04.008; 10.01.04.001; 06.04.01.013--Not Available
Labile hypertension24.08.02.013--Not Available
Muscle tightness15.05.03.007--Not Available
Contusion24.07.06.001; 23.03.11.002; 12.01.06.001; 15.03.05.007--
Viral diarrhoea11.05.04.012; 07.19.02.008--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Epigastric discomfort07.01.02.004--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.001--Not Available
Affect lability19.04.01.001--Not Available
Haemorrhage24.07.01.002--Not Available
Gynaecological examination abnormal13.15.01.021--Not Available
Urine odour abnormal20.02.01.020--Not Available
Paraesthesia oral07.05.05.035; 17.02.06.008--Not Available
Dyslipidaemia14.08.04.015--Not Available
Restless legs syndrome17.02.07.008; 15.05.03.012--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Hot flush24.03.01.005; 08.01.03.027; 21.02.02.001--
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
The 10th Page    First    Pre   10 11    Next   Last    Total 11 Pages